Genetic risk factors for inhibitor development in patients with hemophilia and rare bleeding disorders
- سال انتشار: 1396
- محل انتشار: مجله تحقیقات بیهوشی سلولی و مولکولی، دوره: 2، شماره: 1
- کد COI اختصاصی: JR_SBMU-2-1_003
- زبان مقاله: انگلیسی
- تعداد مشاهده: 443
نویسندگان
Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran
Department of Hematology and Blood Transfusion, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Nursing, Faculty of Medical Sciences, Islamic Azad University, Zahedan Branch, Zahedan, Iran
Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Department of Laboratory Sciences, Paramedical Faculty, Babol University of Medical Sciences, Babol, Iran
Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
چکیده
Inhibitor development is a lifelong challenge for patients with bleeding disorders who received replacement therapy. Most commonly, inhibitor formation was observed in hemophilia a patient, but patients with rare bleeding disorders (RBD) especially patients with deficiency of factor XIII (FXIII) and factor V (FV) can develop an inhibitor against exogenous factors. Several factors considered as risk factors for inhibitor formations in these patients. Genetic risk factors are the main accused that can cause inhibitor formation in hemophilia patients, but are less important in RBDs. In this review study, we searched Medline and Web of Science databases for English sources and the following key words: hemophilia, inhibitor, rare bleeding disorder, a rare inherited disorder, acquired hemophilia, acquired rare bleeding disorders, treatment complication, genetic in hemophilia, polymorphism in rare bleeding disorder, mutation in hemophilia and other required keywords. Hemophilia A (HA) patients who had the large deletion, nonsense mutation or intron 22 inversion are more susceptible to inhibitor development. Gene polymorphisms in the immune system are also considered as other risk factors in HA patients.کلیدواژه ها
Hemophilia, rare bleeding disorder, inhibitorمقالات مرتبط جدید
- دانش سنتی استفاده از گیاهان داروئی توسط زنان روستایی با رویکرد حفاظتی
- Phenolic fraction concentrates supplementation ameliorates learning and memory impairments in chronically stressed streptozotocin-diabetic rats by reducing brain tumor necrosis factor-α
- Chemical composition of Prangos ferulacea (L.) Lindl., and Prangos uloptera DC. essential oils and their antifungal activities
- Effect of ethyl acetate fraction of Costus afer on glycaemic control and essential haematological and biochemical indices of streptozotocin-induced diabetic rats
- Insulin supplemented with phenolic fraction concentrates displays anxiolytic and antidepressant-like properties with reductions of oxidative brain damage in chronically stressed diabetic rats
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.